Filtros de búsqueda

Lista de obras de Bertrand Arnulf

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

scientific article published on 16 December 2019

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

artículo científico publicado en 2016

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis

artículo científico publicado en 2020

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma

scientific article published on 03 February 2020

Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature

scientific article published on 15 December 2019

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

artículo científico publicado en 2017

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

artículo científico publicado en 2020

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

artículo científico publicado en 2017

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Loss of tubular creatinine secretion as the only sign of tubular proximal cell dysfunction in light chain proximal tubulopathy: A case report

artículo científico publicado en 2016

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

artículo científico

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma

artículo científico publicado en 2004

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

artículo científico publicado en 2015

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

artículo científico publicado en 2013

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

artículo científico publicado en 2018

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda